Chennai : EID Parry (India) Limited, one of the largest manufacturers of Sugar in India, has reported its financial results for the quarter ended 30th June 2026.
Consolidated performance for the quarter ended June 30, 2026:
The consolidated revenue from operations for the quarter ended 30th June 2026 was Rs. 9,017 Crore, as compared to Rs. 8,720 crore in the corresponding quarter of the previous year. Earnings before interest, tax, depreciation and amortization (EBITDA) for the quarter ended 30th June 2026 was Rs. 781 Crore, as compared to the Rs. 895 Crore in the corresponding quarter of the previous year. The Consolidated Profit after Tax and non-controlling interest was Rs. 142 Crore as compared to Profit of Rs. 246 Crore in the corresponding quarter of the previous year.
Standalone performance for the quarter ended June 30, 2026:
The Standalone revenue from operations for the quarter ended 30th June 2026 was Rs. 733 Crore as compared to Rs. 756 Crore in the corresponding quarter of previous year. Operational Earnings before interest, tax, depreciation and amortization (EBITDA) for the quarter ended 30th June 2026 was Rs. 23 Crore loss as compared to Loss of Rs. 19 Crore in the corresponding quarter of the previous year.
The Standalone Loss after tax for the quarter was Rs. 89 Crore (which includes Impairment of Investments in subsidiary (PSRIPL) Rs. 19 crores (net) ) as compared to a loss of Rs. 28 Crore in the corresponding quarter of the previous year.
Sugar & Biofuel Division
Consolidated Sugar operations, reported a Loss before Interest and Tax(LBIT) of Rs. 58 Crore for the quarter ended 30th June 2026 as compared to Loss of Rs. 30 Crore in the corresponding quarter of the previous year.
Farm Inputs Division
The Consolidated Farm Inputs operations reported a Profit before Interest and Tax of Rs. 649 Crore for the quarter ended 30th June 2026 as compared to Rs. 741 Crore in the corresponding quarter of the previous year.
Nutraceuticals Division
The Consolidated Nutraceuticals Division reported an LBIT of Rs. 0.11 Crore for the quarter ended 30 June 2026, as compared to a loss of Rs. 10 Crore in the corresponding quarter of the previous year. The improvement in performance was driven by a stronger quarterly performance of the Company’s US Subsidiary – US Nutraceuticals Inc.
Mr. Muthiah Murugappan, Whole-time Director and Chief Executive Officer commenting on the standalone results stated as follows:
Sugar & Biofuel Division:
The Sugar Segment recorded revenue of Rs. 410 Crore for the quarter ended 30 June 2026, compared to Rs. 347 Crore in the corresponding quarter of the previous year, reflecting a growth of 18%, primarily driven by higher sales volumes.
Despite the increase in volumes, the segment reported an LBIT of Rs.49 crore, which remained at the same level as that of the corresponding quarter of the previous year. The benefits arising from higher sales volumes were offset by increased operational costs, including certain one-time expenses incurred during the quarter.
Distillery:
The Distillery Segment recorded revenue of Rs. 255 Crore for the quarter ended 30 June 2026, as compared to Rs. 296 Crore in the corresponding quarter of the previous year, reflecting a decline of 14%. The decline was was primarily attributable to lower off-take of Extra Neutral Alcohol (ENA) by IMFL manufacturers in Tamil Nadu.
The Distillery Segment reported a profit of Rs. 9 Crore for the quarter ended 30 June 2026, as against Rs. 20 Crore in the corresponding quarter of the previous year. The decline in profitability was primarily due to lower realisations coupled with increased operational costs during the quarter.
Consumer Products Group (CPG):
The Consumer Products Group (CPG) reported revenue of Rs. 94 Crore for the quarter ended 30 June 2026, compared to Rs. 188 Crore in the corresponding quarter of the previous year.
Despite the decline in revenue, the segment recorded an improvement in operating margins, driven by a deliberate recalibration of its operating model and a sharper focus on profitability.
Nutraceuticals:
The Nutraceuticals segment reported revenue of Rs. 6 Crore for the quarter ended 30 June 2026, which was in line with the corresponding quarter of the previous year. The segment reported a profit of Rs. 0.01 Crore, compared to a loss of Rs. 0.20 Crore in the corresponding quarter of the previous year, reflecting improved profitability driven by enhanced operational efficiencies.
